|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bobdey S, Jain A and Balasubramanium G:
Epidemiological review of laryngeal cancer: An Indian perspective.
Indian J Med Paediatr Oncol. 36:154–160. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
(India) NCRP. India population based
cancer registries 2009-2011 Bangalore: Indian Council of Medical
Research (ICMR); 2013. Available from: https://ncdirindia.org/NCRP/ALL_NCRP_REPORTS/PBCR_REPORT_2009_2011/ALL_CONTENT/Printed_Version.htm.
|
|
4
|
https://www.cancer.org/cancer/laryngeal-and-hypopharyngealcancer/detection-diagnosis-staging/survival-rates.html.
|
|
5
|
Brandstorp-Boesen J, Sorum Falk R,
Folkvard Evensen J, Boysen M and Brondbo K: Risk of recurrence in
laryngeal cancer. PLoS One. 11(e0164068)2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Johansen LV, Grau C and Overgaard J:
Laryngeal carcinoma-multivariate analysis of prognostic factors in
1252 consecutive patients treated with primary radiotherapy. Acta
Oncol. 42:771–778. 2003.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rothman KJ, Cann CI, Flanders D and Fried
MP: Epidemiology of laryngeal cancer. Epidemiol Rev. 2:195–209.
1980.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Clemente CD: Anatomy; A regional atlas of
human body. Philadelphia PA; lea and febiger, 1975.
|
|
9
|
Muscat JE and Wynder EL: Tobacco, alcohol,
asbestos, and occupational risk factors for laryngeal cancer.
Cancer. 69:2244–2251. 1992.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Graham S: Diet and cancer. Am J Epidemiol.
112:247–252. 1980.
|
|
11
|
Ward PH and Hanson DG: Reflux as an
etiological factor of carcinoma of the laryngopharynx.
Laryngoscope. 98:1195–1199. 1988.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bacciu A, Mercante G, Ingegnoli A, Ferri
T, Muzzetto P, Leandro G, Di Mario F and Bacciu S: Effects of
gastroesophageal reflux disease in laryngeal carcinoma. Clin
Otolaryngol Allied Sci. 29:545–548. 2004.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mao L, Hong WK and Papadimitrakopoulou VA:
Focus on head and neck cancer. Cancer Cell. 5:311–316.
2004.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Almadori G, Bussu F, Cadoni G, Galli J,
Paludetti G and Maurizi M: Molecular markers in laryngeal squamous
cell carcinoma: Towards an integrated clinicobiological approach.
Eur J Cancer. 41:683–693. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kapral M, Strzalka B, Kowalczyk M, Jurzak
M, Mazurek U, Gierek T, Paluch J, Markowski J, Swiatkowska L and
Weglarz L: Transforming growth factor beta isoforms (TGF-beta1,
TGF-beta2, TGF-beta3) messenger RNA expression in laryngeal cancer.
Am J Otolaryngol. 29:233–237. 2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Loyo M and Pai SL: The molecular genetics
of laryngeal cancer. Otolaryngol Clin North Am. 41:657–672, v.
2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yoo SS, Carter D, Turner BC, Sasaki CT,
Son YH, Wilson LD, Glazer PM and Haffty BG: Prognostic significance
of cyclin D1 protein levels in early-stage larynx cancer treated
with primary radiation. Int J Cancer. 90:22–28. 2000.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Department of Veterans Affairs Laryngeal
Cancer Study Group. Wolf GT, Fisher SG, Hong WK, Hillman R,
Spaulding M, Laramore GE, Endicott JW, McClatchey K and Henderson
WG: Induction chemotherapy plus radiation compared with surgery
plus radiation in patients with advanced laryngeal cancer. N Engl J
Med. 324:1685–1690. 1991.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Urba S, Wolf G, Eisbruch A, Worden F, Lee
J, Bradford C, Teknos T, Chepeha D, Prince M, Hogikyan N and Taylor
J: Single-cycle induction chemotherapy selects patients with
advanced laryngeal cancer for combined chemoradiation: A new
treatment paradigm. J Clin Oncol. 24:593–598. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Fung K, Lyden TH, Lee J, Urba SG, Worden
F, Eisbruch A, Tsien C, Bradford CR, Chepeha DB, Hogikyan ND, et
al: Voice and swallowing outcomes of an organ-preservation trial
for advanced laryngeal cancer. Int J Radiat Oncol Biol Phys.
63:1395–1399. 2005.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lacas B, Carmel A, Landais C, Wong SJ,
Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, et al:
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An
update on 107 randomized trials and 19,805 patients, on behalf of
MACH-NC group. Radiother Oncol. 156:281–293. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Pignon JP, Bourhis J, Domenge C and
Designé L: Chemotherapy added to locoregional treatment for head
and neck squamous-cell carcinoma: Three meta-analyses of updated
individual data. MACH-NC collaborative group. Meta-analysis of
chemotherapy on head and neck cancer. Lancet. 355:949–955.
2000.PubMed/NCBI
|
|
23
|
Bourhis J, Amand C and Pignon JP: Update
of MACH-NC (meta-analysis of chemotherapy in head & neck
cancer) database focused on concomitant chemoradiotherapy. J Clin
Oncol. 22 (14 Suppl)(S5505)2004.
|
|
24
|
Pignon JP, le Maître A, Maillard E and
Bourhis J: MACH-NC Collaborative Group. Meta-analysis of
chemotherapy in head and neck cancer (MACH-NC): An update on 93
randomised trials and 17,346 patients. Radiother Oncol. 92:4–14.
2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Blanchard P, Baujat B, Holostenco V,
Bourredjem A, Baey C, Bourhis J and Pignon JP: MACH-CH
Collaborative group. Meta-analysis of chemotherapy in head and neck
cancer (MACH-NC): A comprehensive analysis by tumour site.
Radiother Oncol. 100:33–40. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Forastiere AA, Goepfert H, Maor M, Pajak
TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et
al: Concurrent chemotherapy and radiotherapy for organ preservation
in advanced laryngeal cancer. N Engl J Med. 349:2091–2098.
2003.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Forastiere AA, Zhang Q, Weber RS, Maor MH,
Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, et
al: Long-term results of RTOG 91-11: A comparison of three
nonsurgical treatment strategies to preserve the larynx in patients
with locally advanced larynx cancer. J Clin Oncol. 31:845–852.
2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bhattacharyya T and Kainickal CT: Current
Status of organ preservation in carcinoma larynx. World J Oncol.
9:39–45. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
http://www.cancerstaging.org/.
|
|
30
|
Vermorken JB, Remenar E, van Herpen C,
Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss
JH, et al: Cisplatin, fluorouracil, and docetaxel in unresectable
head and neck cancer. N Engl J Med. 357:1695–1704. 2007.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lorch JH, Goloubeva O, Haddad RI, Cullen
K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE and Posner
MR: TAX 324 Study Group. Induction chemotherapy with cisplatin and
fluorouracil alone or in combination with docetaxel in locally
advanced squamous-cell cancer of the head and neck: Long-term
results of the TAX 324 randomised phase 3 trial. Lancet Oncol.
12:153–159. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Pointreau Y, Garaud P, Chapet S, Sire C,
Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M and Calais
G: Randomized trial of induction chemotherapy with cisplatin and
5-fluorouracil with or without docetaxel for larynx preservation. J
Natl Cancer Inst. 101:498–506. 2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Posner MR, Hershock DM, Blajman CR,
Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM,
Cullen K, Ervin TJ, et al: Cisplatin and fluorouracil alone or with
docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715.
2007.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cohen EE, Karrison TG, Kocherginsky M,
Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB,
Yunus F, et al: Phase III randomized trial of induction
chemotherapy in patients with N2 or N3 locally advanced head and
neck cancer. J Clin Oncol. 32:2735–2743. 2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Haddad R, O'Neill A, Rabinowits G, Tishler
R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, et
al: Induction chemotherapy followed by concurrent chemoradiotherapy
(sequential chemoradiotherapy) versus concurrent chemoradiotherapy
alone in locally advanced head and neck cancer (PARADIGM): A
randomised phase 3 trial. Lancet Oncol. 14:257–264. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Budach W, Bölke E, Kammers K, Gerber PA,
Orth K, Gripp S and Matuschek C: Induction chemotherapy followed by
concurrent radio-chemotherapy versus concurrent radio-chemotherapy
alone as treatment of locally advanced squamous cell carcinoma of
the head and neck (HNSCC): A meta-analysis of randomized trials.
Radiother Oncol. 118:238–243. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Trial of laryngeal preservation comparing
induced CT followed by RT vs CT concomitant to RT
(SALTORL)-NCT03340896. ClinicalTrials.gov, 2022.
|
|
38
|
Lacy PD, Piccirillo JF, Merritt MG and
Zequeira MR: Head and neck squamous cell carcinoma: Better to be
young. Otolaryngol Head Neck Surg. 122:253–258. 2000.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Brandstorp-Boesen J, Falk RS, Boysen M and
Brøndbo K: Long-term trends in gender, T-stage, subsite and
treatment for laryngeal cancer at a single center. Eur Arch
Otorhinolaryngol. 271:3233–3239. 2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Browman GP, Wong G, Hodson I, Sathya J,
Russell R, McAlpine L, Skingley P and Levine MN: Influence of
cigarette smoking on the efficacy of radiation therapy in head and
neck cancer. N Engl J Med. 328:159–163. 1993.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Fortin A, Wang CS and Vigneault E:
Influence of smoking and alcohol drinking behaviors on treatment
outcomes of patients with squamous cell carcinomas of the head and
neck. Int J Radiat Oncol Biol Phys. 74:1062–1069. 2009.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Fong PY, Tan SH, Lim DWT, Tan EH, Ng QS,
Sommat K, Tan DSW and Ang MK: Association of clinical factors with
survival outcomes in laryngeal squamous cell carcinoma (LSCC). PLoS
One. 14(e0224665)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Bøje CR, Dalton SO, Grønborg TK, Primdahl
H, Kristensen CA, Andersen E, Johansen J, Andersen LJ and Overgaard
J: The impact of comorbidity on outcome in 12 623 Danish head and
neck cancer patients: A population based study from the DAHANCA
database. Acta Oncol. 52:285–293. 2013.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Karlsson TR, Al-Azzawe M, Aziz L, Hurman D
and Finizia C: Survival outcome depending on different treatment
strategies in advanced stages III and IV laryngeal cancers: An
audit of data from two European centres. Eur Arch Otorhinolaryngol.
271:547–554. 2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Gourin CG, Conger BT, Sheils WC, Bilodeau
PA, Coleman TA and Porubsky ES: The effect of treatment on survival
in patients with advanced laryngeal carcinoma. Laryngoscope.
119:1312–1317. 2009.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Weber RS, Berkey BA, Forastiere A, Cooper
J, Maor M, Goepfert H, Morrison W, Glisson B, Trotti A, Ridge JA,
et al: Outcome of salvage total laryngectomy following organ
preservation therapy: The radiation therapy oncology group trial
91-11. Arch Otolaryngol Head Neck Surg. 129:44–49. 2003.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Daneshi N, Fararouei M, Mohammadianpanah
M, Zare-Bandamiri M, Parvin S and Dianatinasab M: Effects of
different treatment strategies and tumor stage on survival of
patients with advanced laryngeal carcinoma: A 15-year cohort study.
J Cancer Epidemiol. 2018(9678097)2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan
PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar
AK, et al: Randomized phase III trial of concurrent accelerated
radiation plus cisplatin with or without cetuximab for stage III to
IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 32:2940–2950.
2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Patil VM, Noronha V, Joshi A, Agarwal J,
Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, Mahimkar M, Juvekar
S, et al: A randomized phase 3 trial comparing nimotuzumab plus
cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy
alone in locally advanced head and neck cancer. Cancer.
125:3184–3197. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Eriksen JG, Maare C, Johansen J, Primdahl
H, Evensen JF, Kristensen CA, Andersen LJ and Overgaard J:
Evaluation of the EGFR-inhibitor zalutumumab given with primary
curative (Chemo) radiation therapy to patients with squamous cell
carcinoma of the head and neck: Results of the DAHANCA 19
randomized phase 3 trial: Definitive management of head-and-neck
squamous. Int J Radiat Oncol Biol Phys. 88(P465)2014.
|
|
51
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Bonner JA, Harari PM, Giralt J, Cohen RB,
Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al:
Radiotherapy plus cetuximab for locoregionally advanced head and
neck cancer: 5-Year survival data from a phase 3 randomised trial,
and relation between cetuximab-induced rash and survival. Lancet
Oncol. 11:21–28. 2010.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Chow LQM, Haddad R, Gupta S, Mahipal A,
Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, et al:
Antitumor activity of pembrolizumab in biomarker-unselected
patients with recurrent and/or metastatic head and neck squamous
cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion
cohort. J Clin Oncol. 34:3838–3845. 2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Cohen EEW, Soulières D, Le Tourneau C,
Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R,
et al: Pembrolizumab versus methotrexate, docetaxel, or cetuximab
for recurrent or metastatic head-and-neck squamous cell carcinoma
(KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet.
393:156–167. 2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Yu Y and Lee NY: JAVELIN head and neck
100: A phase III trial of avelumab and chemoradiation for locally
advanced head and neck cancer. Future Oncol. 15:687–694.
2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee
SK, Ahn YC, Jeong HS, Son YI, Baek JH and Park K: ERCC1 expression
as a predictive marker of squamous cell carcinoma of the head and
neck treated with cisplatin-based concurrent chemoradiation. Br J
Cancer. 99:167–172. 2008.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Lefebvre JL and Ang KK: Larynx
Preservation Consensus Panel. Larynx preservation clinical trial
design: Key issues and recommendations-a consensus panel summary.
Head Neck. 31:429–441. 2009.PubMed/NCBI View Article : Google Scholar
|
